Cellectar Biosciences Inc (CLRB) concluded trading on Thursday at a closing price of $0.30, with 12.92 million shares of worth about $3.88 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -85.87% during that period and on March 13, 2025 the price saw a loss of about -5.37%. Currently the company’s common shares owned by public are about 46.08M shares, out of which, 45.31M shares are available for trading.
Stock saw a price change of -2.22% in past 5 days and over the past one month there was a price change of 4.03%. Year-to-date (YTD), CLRB shares are showing a performance of 0.20% which decreased to -92.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $4.17 during that period. The average intraday trading volume for Cellectar Biosciences Inc shares is 2.04 million. The stock is currently trading -0.66% below its 20-day simple moving average (SMA20), while that difference is up 4.11% for SMA50 and it goes to -81.54% lower than SMA200.
Cellectar Biosciences Inc (NASDAQ: CLRB) currently have 46.08M outstanding shares and institutions hold larger chunk of about 11.18% of that.
The stock has a current market capitalization of $13.81M and its 3Y-monthly beta is at 0.66. It has posted earnings per share of -$1.87 in the same period. It has Quick Ratio of 1.77 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLRB, volatility over the week remained 9.53% while standing at 8.82% over the month.
Stock’s fiscal year EPS is expected to rise by 52.86% while it is estimated to decrease by -28.79% in next year. EPS is likely to shrink at an annualized rate of 22.27% for next 5-years, compared to annual growth of 41.77% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on December 05, 2024 offering a Buy rating for the stock and assigned a target price of $13 to it. Stock get a Buy rating from Ladenburg Thalmann on December 21, 2016.
